Manufacturing process of ApoNV-DC and its myocardial infarction treatment mechanism
[충청뉴스 이성현 기자] The Korea Institute of Science and Technology (KIST) has developed a new myocardial infarction treatment method that regulates the immune response by utilizing nano-endoplasmic reticulum derived from fibroblasts in which apoptosis is induced by a research team led by Senior Researcher Jung Yoon-ki and Dr. Lee Ju-ro at the Biomaterials Research Center. It was announced on the 6th that it was developed.
Myocardial infarction is an ischemic heart disease in which coronary arteries, which supply blood to the heart, are narrowed or blocked, preventing sufficient blood supply to the heart muscle and causing nutrient and oxygen deficiency in the heart muscle, resulting in poor heart function.
The research team confirmed the possibility of treating severe myocardial infarction by reducing the inflammatory response of the heart muscle through nanomedicines made from apoptotic cells that commit suicide by intracellular biochemical changes.
This response was possible by attaching peptides specific to the ischemic myocardial infarction disease site and substances specific to macrophage feeding to the surface of fibroblasts. developed nano-endoplasmic reticulum that can be specifically delivered to macrophages in the myocardial infarction area while having
In animal experiments, it was confirmed that nanovesicles injected intravenously into mice were effectively delivered to the myocardial infarction site and that a large amount was specifically introduced only to macrophages.
As a result, the left ventricular ejection fraction (LVEF), an indicator of contractility of the left ventricle, increased more than 1.5 times compared to the control group for 4 weeks, confirming the effect of improving cardiac output. In addition, it reduces inflammation in the myocardial infarction area, reduces fibrosis in the myocardial infarction area, and improves heart function, such as the preservation rate of blood vessels in the heart and the survival rate of cardiomyocytes.
Dr. Jung Yoon-gi of KIST said, “This is the first study to apply nano-endoplasmic reticulum produced from apoptosis-induced cells to the treatment of myocardial infarction disease. We plan to conduct research to verify the efficacy and safety of treatment, such as clinical trials, through joint research with the Catholic University of Korea Medical School and bio companies.”
Copyright © Chungcheong News Unauthorized reproduction and redistribution prohibited
Did you like the article?
Chungcheong News Sponsor good articles
2023-08-06 11:54:18
#KIST #develops #myocardial #infarction #treatment #controlling #immune #response
